Related Experiment Video
Updated: Mar 30, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives
1Department of Biomedical Sciences & Pathobiology, Center for Molecular Medicine & Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute & State University, Blacksburg, VA 24061-0913, USA.
Abstract:
Human noroviruses (HuNoVs) are a leading cause of acute, nonbacterial gastroenteritis worldwide. The lack of a cell culture system and smaller animal model has delayed the development and commercial availability of vaccines and antiviral drugs. Current vaccines rely on recombinant capsid proteins, such as P particles and virus-like particles (VLPs), which have been promising in clinical trials. Anti-HuNoV drug development is another area of extensive research, including currently available antiviral drugs for other viral pathogens. This review will provide an overview of recent advances in vaccine and antiviral development. The implication of recent advances in HuNoV cell culture for improving vaccine and antiviral development is also discussed.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Microorganisms in Medicine and Therapeutics
FDA Approved Drugs: Changes to Approved Drugs
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

